Radiotherapy in Breast Cancer in Single Institute Study experience: comparing Extreme Hypofractionation to Moderate Hypofractionation
Keywords:
Breast Cancer, Hypofractionation Radiotherapy, OutcomeAbstract
Background: Breast carcinoma is a common malignancy in Iraq. Radiotherapy is an essential line of breast cancer treatment. Nationally, hypofractionation radiotherapy has successfully implemented in the management of breast cancer.
Aim of study: To compare the efficacy and safety of extreme hypofractionation with moderate hypofractionation radiotherapy in breast cancer management.
Patients & Methods: A retrospective review was conducted on medical records for one hundreds of women with breast cancers in different stages, whose treated with two different hypofractionated radiotherapy regimens in Zhianawa Cancer Center Sulaimani-Iraq between July 2015 and December, 2019. Fifty patients had taken for each treatment group. The patients followed up for four years through regular visits of patients to the Zhianawa cancer center or by phone call.
Results: There was a significant difference between comparing groups regarding the utilization of boost (p<0.001), survival outcomes (p=0.003), and distant metastasis (p=0.001). The disease outcomes of patients managed by extreme hypofractionation protocol were close to those treated by moderate protocol. The higher death rate and distant metastasis in patients treated with extreme hypofractionation were substantially due to more advanced disease stages.
Conclusions: The Extreme hypofractionation radiotherapy is an effective and safe treatment option for breast cancer. Although differences in survival outcome and distant metastasis, the extreme hypofractionation is non-inferior to moderate hypofractionation schedules in median survival, locoregional recurrence, and late side effects
Downloads
References
Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, et al. Current controversies in radiotherapy for breast cancer. Radiat Oncol 2017; 12(1):25.
Van Londen G, Beckjord EB, Dew MA, Cuijpers P, Tadic S, Brufsky A. Breast cancer survivorship symptom management: Current perspective and future development. Breast Cancer Management 2013; 2(1):71-81.
Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American cancer society/(American society of clinical oncology) breast cancer survivorship care guideline. CA: A Cancer Journal for Clinicians. 2016;66(1):43-73.
Ahmed HA, Ruanduzy LQA, Yousi PH. Breast cancer among women of Erbil. Iraq's Kurdistan Region. Int. J. Adv. Res 2016; 4(9): 214-221.
Torre LA. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2012; 65(2):87-108.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods, and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015; 136(5): E359-E386.
Saslow D. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians. 2007; 57(2):75-89.
Haber G, Ahmed NU, Pekovic V. Family history of cancer and its association with breast cancer risk perception and repeat mammography. American Journal of Public Health 2012; 102(12):2322-2329.
Rah B, Ali S, Dar MI, Afroze D. Breast Cancer: Management and Survivorship. Intech Open 2019. Available at:https://www.intechopen.com/books/cancer-survivorship/breast-cancer-management- and-survivorship
Sanz J, Zhao M, Rodríguez N, Granado R, Foro P, Reig A, et al. Once-Weekly Hypofractionated Radiotherapy for Breast Cancer in Elderly Patients: Efficacy and Tolerance in 486 Patients. Biomed Res Int 2018; 2018:8321871.
McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical Diagnosis and Management of Breast Cancer. J Nucl Med 2016; 57 Suppl 1:9S-16S.
Anderson SJ, Wapnir I, Dignam JJ. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 2009; 27:2466–2473.
Haviland JS, A'Hern R, Bentzen SM, Whelan T, Bliss JM. Radiotherapy for breast cancer, the TARGIT-A trial. Lancet, 2014; 383:1716,–1717.
Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. After 12 years of follow-up in a randomized clinical trial, reanalysis, and results compared total mastectomy with lumpectomy with or without irradiation in breast cancer treatment. The New England Journal of Medicine 1995; 333(22):1456–1461.
Algara M, Salinas J. Controversies in Radiotherapy for Breast Cancer. Madrid, Spain: GlaxoSmithKline; 2010. Radiation therapy in breast cancer. Standard treatment and controversies; pp. 67–72.
Smith BD, Bellon JR, Blitzblau R. Radiation therapy for the whole breast: executive summary of an American Society of Radiation Oncology (ASTRO) evidence-based guideline. PractRadiat Oncol 2018; 8:145-152.
START Trialists' Group, Bentzen SM, Agrawal RK. The UK standardized breast radiotherapy (START) Trial A of radiotherapy hypofractionation for early breast cancer treatment: a
randomized trial. Lancet Oncol 2008; 9:331-341.
START Trialists' Group, Bentzen SM, Agrawal RK. The UK standardized breast radiotherapy (START) Trial B of radiotherapy hypofractionation for early breast cancer treatment: a randomized trial. Lancet 2008; 371:1098-1107.
Whelan TJ, Pignol JP, Levine MN. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362:513-520.
Whelan T, MacKenzie R, Julian J. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002; 94:1143-1150.
Al-Naqqash MA, Al-Bdaer EK, Saleh Saleh WA, and Al Shewered AS. Progression-free survival in Iraqi breast cancer patients treated with adjuvant 3D conformal radiotherapy: A cross-sectional study [version 1; peer review: 1 approved with reservations] F1000Research 2019; 8: 71.
Majid RA, Mohammed HA, Saeed HM, Safar BM, Rashid RM, Hughson MD. Breast cancer in Kurdish women of northern Iraq: incidence, clinical stage, and case-control analysis of parity and family risk. BMC Women's Health, 2009; 9:33.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P. Effect of radiotherapy after breast-conserving surgery on 10year recurrence and 15-year breast cancer death: a meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 2011; 378:1707-1716.
EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality meta-analysis of individual patient data for 8135 women in 22 randomized trials. Lancet 2014; 383:2127-2135.
Bhattacharyya T, Mahajan R, Ghoshal S, Yadav BS, Rai B. Hypofractionated radiotherapy in carcinoma breast: What we have achieved? J Cancer Res Ther 2015; 11(2):259-263.
Budach W, Bölke E, Matuschek C. Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-analysis of Randomized Controlled Trials. Breast Care (Basel) 2015; 10(4):240‐245.
Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al.; FAST- Forward Trial Management Group. Hypofractionated breast radiotherapy for one week versus three weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomized, phase 3 trial. The Lancet 2020: 1-14. Available at: www.thelancet.com
Dragun AE, Ajkay NJ, Riley EC, Roberts TL, Pan J, Rai SN, et al. First Results of a Phase 2 Trial
of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys 2017; 98(3):595-602.
Amouzegar Hashemi F, Barzegartahamtan M, Mohammadpour RA, Sebzari A, Kalaghchi B, Haddad P. Comparison of Conventional and Hypofractionated Radiotherapy in Breast Cancer Patients in Terms of 5-Year Survival, Locoregional Recurrence, Late Skin Complications, and Cosmetic Results. Asian Pac J Cancer Prev 2016; 17(11):4819‐4823.
Rivera S, Hannoun-Lévi JM. Hypofractionated radiation therapy for invasive breast cancer: From
moderate to extreme protocols. Cancer Radiother 2019; 23(8):874-882.
Harnett A. Fewer fractions of adjuvant external beam radiotherapy for early breast cancer are safe and effective and can now be standard care. The UK's NICE accepts fewer fractions as the standard of care for adjuvant radiotherapy in early breast cancer. Breast 2010; 19:159-162.
Gupta A, Ohri N, Haffty BG. Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 2018; 18(8):793‐803.
Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for one week versus three weeks (FAST-Forward): 5-year efficacy and late normal tissue effects result from a multicentre, non-inferiority, randomized, phase 3 trial. Lancet. 2020;395(10237):1613- 1626. DOI:10.1016/S0140-6736(20)30932-6
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
